Clinical Trials · NCT05879926
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- NRG Oncology
- Enrollment
- 3,960
- Start date
- Oct 2023
- Locations
- 1243 sites, 8 countries
- Primary endpoint
- Invasive breast cancer-free survival (IBCFS)